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Abstract
Background: An ancillary finding in previous research has suggested that the use of antidepressant medications
increases the risk of developing Clostridium difficile infection (CDI). Our objective was to evaluate whether
depression or the use of anti-depressants altered the risk of developing CDI, using two distinct datasets and study
designs.
Methods: In Study 1, we conducted a longitudinal investigation of a nationally representative sample of older
Americans (n = 16,781), linking data from biennial interviews to physician and emergency department visits, stays in
hospital and skilled nursing facilities, home health visits, and other outpatient visits. In Study 2, we completed a
clinical investigation of hospitalized adults who were tested for C. difficile (n = 4047), with cases testing positive and
controls testing negative. Antidepressant medication use prior to testing was ascertained.
Results: The population-based rate of CDI in older Americans was 282.9/100,000 person-years (95% confidence
interval (CI)) 226.3 to 339.5) for individuals with depression and 197.1/100,000 person-years for those without
depression (95% CI 168.0 to 226.1). The odds of CDI were 36% greater in persons with major depression (95% CI
1.06 to 1.74), 35% greater in individuals with depressive disorders (95% CI 1.05 to 1.73), 54% greater in those who
were widowed (95% CI 1.21 to 1.95), and 25% lower in adults who did not live alone (95% CI 0.62 to 0.92). Self-
reports of feeling sad or having emotional, nervous or psychiatric problems at baseline were also associated with
the later development of CDI. Use of certain antidepressant medications during hospitalization was associated with
altered risk of CDI.
Conclusions: Adults with depression and who take specific anti-depressants seem to be more likely to develop
CDI. Older adults who are widowed or who live alone are also at greater risk of CDI.
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Background
Clostridium difficile infection (CDI) is the most com-
monly diagnosed cause of antibiotic-associated diarrhea,
and has emerged as a major nosocomial infection, sur-
passing methicillin-resistant Staphylococcus aureus in
some hospitals [1]. In addition to causing more than
7,000 deaths annually in the USA [2], it is prevalent in
hospitals throughout Europe, with a mean frequency of
23 cases for every 10,000 admissions [3]. Concerted ef-
forts are ongoing to identify modifiable risk factors for
CDI, motivated by the need for better preventive and
therapeutic options against this infection.
Modifiable risk factors for CDI include several classes
of medications such as proton-pump inhibitors (PPIs)
and histamine-2 receptor antagonists (H2RAs) [4]. Anti-
depressants have also been implicated in this infection
[5]. In a cohort study of 14,719 hospitalized patients, an
ancillary finding of an association between antidepres-
sant medications and CDI was reported, which was
stronger than that found for PPIs or H2RAs [5]. A pos-
sible link between antidepressant medications and CDI
is noteworthy because depression is the third most
prevalent disabling condition worldwide, as reported by
the World Health Organization [6]. Effects of depression
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have been shown to include alterations in the gut micro-
biota and increased intestinal permeability [7-9]. In the
murine model, behavioral depression increases jejunal
permeability and susceptibility to colitis [10]. In
population-based human studies, depression was found
to be significantly predictive of inflammatory bowel dis-
ease [11,12].
Since the publication of the study by Dalton et al.
linking antidepressant use with the risk of CDI [5], there
has been no evidence, to our knowledge, to support or re-
fute this finding. Therefore, we planned an investigation to
assess whether depression or the use of anti-depressants
alters the risk of CDI. We tested these hypotheses using
two distinct but complementary approaches. First, we as-
sembled longitudinal data from a nationally representative
sample of older Americans so that these relationships
could be assessed in a more generalizable population. Sec-
ond, we utilized a clinical database of adults admitted to
an academic hospital to obtain details regarding anti-
depressant use.
Methods
Ethics approval
The studies received human subjects approval at the
University of Michigan. Patient consent was obtained for
subjects who participated in the Health and Retirement
Study. Because retrospective electronic data were used
for the clinical study, patient consent was waived.
Study 1
We conducted a longitudinal study to determine popula-
tion rates of CDI in individuals with and without depres-
sion, and to evaluate the association between depression
and CDI. Subjects were participants in the nationally
representative Health and Retirement Study (HRS),
which is an ongoing longitudinal study of older Ameri-
cans. Details of the study design of the HRS and subject
characteristics have been published previously [13].
Households were selected using multistage area prob-
ability sampling from the National Sample frame, with
random selection of eligible individuals within the
household. Subjects were interviewed every 2 years; data
from interviews during years 1992–2006 were used in
the present investigation. Data from the interviews were
linked to files from the Centers for Medicare and Medic-
aid Services (CMS) covering the period 1991–2007, for
fee-for-service beneficiaries. The CMS Standard Analyt-
ical Files used were the Inpatient, Outpatient, Skilled
Nursing Facility, Carrier (Part B), Home Health Agency,
and Denominator files.
CDI was based on diagnosis by a physician of CDI
(ICD-9-CM code 008.45) recorded in Inpatient, Out-
patient, Carrier, Skilled Nursing Facility or Home Health
Agency files. This captured both outpatient and inpatient
diagnoses of CDI. The positive and negative predictive
values of the ICD-9-CM code for identifying CDI have
been previously reported as 87% and 96%, respectively
[14]. Depression was determined from a physician diagno-
sis of major depression (ICD-9-CM codes 296.2×, 296.3×,
300.4, 311) at any time prior to diagnosis of CDI. We also
captured a wider group of patients with ‘depressive disor-
ders’ which included brief or prolonged depressive reac-
tions, adjustment reaction with anxiety and depression,
depressive type psychosis, chronic depressive personality
disorder, bipolar affective disorder with depression, neur-
otic depression, depressive disorder (not elsewhere classi-
fied), and major depression (ICD-9-CM codes 296.2×,
296.3×, 296.5, 298.0, 300.4, 301.12, 309.0, 309.1, 309.28,
311, V79.0) diagnosed at any time prior to the diagnosis of
CDI. Psychiatrist visits were determined from the Carrier
(individual provider) file using Berenson-Eggers Type of
Service (BETOS) code M5B (evaluation and management
by a specialist – psychiatry). Other items related to de-
pression were determined from the initial interview of the
HRS. The questions were: ‘During the past week, did you
feel sad?’ and ‘Did a doctor ever tell you that you had emo-
tional, nervous or psychiatric problems?’ We also assessed
marital status at the time of the first interview (married or
partnered, divorced or separated, single, widowed). As
household information was available, we also extracted
data regarding the number of people in the household at
the time of the first interview.
Information was also extracted from the HRS for year
of birth, gender, race, ethnicity, region of residence
(northeast, midwest, south, west), body mass index
(BMI; kg/m2) at the time of the first interview, smoking
status at the time of the first interview (never, former,
current), end-stage renal disease at the time of the first
interview, and diagnoses of Crohn’s disease, irritable
bowel syndrome, ulcerative colitis, or celiac disease
(prior to the first CDI diagnosis for those with CDI). We
anticipated that some individuals would have greater
contact with physicians and medical services and, there-
fore, we also calculated the number of infection-related
visits (inpatient and outpatient) and the total number of
medical-related visits (inpatient and outpatient) over the
entire period of observation for each subject. The num-
ber of infection-related visits was the crude proxy for
exposure to antibiotics. Missing values were imputed
for the variables of race (n = 37), ethnicity (n = 3), region
of residence (n = 28), BMI (n = 30) and smoking status
(n = 91). The calendar year of the first interview was also
included to account for secular trends.
Survey-weighted population-based rates of CDI (num-
ber of individuals with the diagnosis of CDI per 100,000
person-years of observation) were calculated for individ-
uals with and without major depression. The rates were
stratified by subject characteristics (age, gender, race,
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ethnicity, BMI, education and region of residence).
Survey-weighted logistic regression (svy: logistic) was
used to assess the association between depression and
CDI, offset by the natural log of the person-years under
observation, after adjustment for year of birth (centered),
gender, race, ethnicity, BMI, smoking, end-stage renal
disease, Crohn’s disease, celiac disease, ulcerative colitis,
irritable bowel disease, number of infection-related
visits, and total number of medical-related visits. Alpha
was set at 0.05, two-tailed.
Study 2
A hospital-based case–control study was conducted to
evaluate the association between antidepressant medica-
tions and hospital-acquired CDI. Subjects were all adult
patients (18 years or older) hospitalized in the University
of Michigan Health System (UMHS) during the period
August 2010 to February 2012, who had their stools
tested for C. difficile. Stool was tested for C. difficile by
the UMHS Clinical Microbiology Laboratory. Testing
was performed on stools for glutamate dehydrogenase
(GDH) antigen and toxins A or B (C. DIFF QUIK CHEK
COMPLETE® test; Techlab, Inc., Blacksburg, VA, USA).
All antigen/toxin discordant stool tests were subjected
to analysis for the tcdB gene by real-time PCR (BD
GeneOhm™ Cdiff Assay; Franklin Lakes, NJ, USA). Be-
cause hospital-acquired infection was of interest, pa-
tients admitted for reason of C. difficile (principal
diagnosis of CDI) were excluded. Cases were patients
who tested positive for CDI at 48 hours or longer after
admission and controls were patients who tested nega-
tive for CDI at 48 hours or longer after admission. Be-
cause CDI testing is usually ordered for symptomatic
patients (for example, those with antibiotic-associated
diarrhea), cases and controls were suspected a priori to
be fairly concordant on these general characteristics. For
individuals with multiple C. difficile tests, the first test
result was used for the purposes of this study. Data re-
garding patient demographics, comorbidities and medi-
cations (prior to the date of stool collection for CDI
testing) were extracted from the electronic hospital data
system. Detailed information was available for the dos-
ages and dates in which medications were given to each
patient.
To assess differences in patient characteristics by
case–control status, Pearson’s χ2 test for categorical data,
Student’s t-test for differences in mean age, and the
Kruskal-Wallis test for differences in length of stay prior
to stool collection were used. Unconditional logistic re-
gression was used to assess the association between anti-
depressant use and CDI, with and without adjustment
for age, gender, race, antibacterial medications, PPIs,
H2RAs, statins, irritable bowel syndrome, celiac disease,
Crohn’s disease and ulcerative colitis.
Finally, we conducted a sensitivity analysis for the case–
control study using different controls. We conducted a
case-crossover study in which each patient served as his/
her own control, to evaluate differences in anti-depressants
while controlling for any history of depression. This ana-
lysis incorporates a within-person comparison in which the
use of medications is compared over different time periods
for the same patient and therefore, it can be used to separ-
ate the effects of the anti-depressants from the effects of
the disease itself (pathophysiology of depression). Such an
approach also controls for factors that are difficult to cap-
ture, such as genetic profile and past dietary habits. UMHS
hospitalizations in which hospital-acquired CDI occurred
(n = 406) were compared with subsequent hospitalizations
(n = 949) for the same patient in which CDI did not occur
(July 2009 to June 2012). Odds ratios (ORs) were calcu-
lated using a conditional logit model for panel data (clogit),
offset by the natural log of the time at risk for infection
(length of stay for hospitalizations without CDI; length of
time from admission to stool collection for positive C. diffi-
cile for hospitalizations with CDI). Statistical analyses were
performed by using Stata/MP 11.2 (StataCorp LP, College
Station, TX, USA). Alpha was set at 0.05, two -tailed.
Results
Study 1
The age (mean ± SD) of the 16,781 participants in the
linked HRS-CMS database at the time of the first inter-
view was 67.9 ± 10.6 years and 56.2% were women
(Table 1). At baseline, the majority were either over-
weight (BMI 25.0 to 29.9 kg/m2) or obese (BMI ≥30
kg/m2). Of the 16,781 subjects, 404 had been diagnosed
with CDI at least once, according to their Medicare re-
cords. Of these 404 people diagnosed with CDI, 142
(35%) had received a diagnosis of major depression and
150 (37%) had received a diagnosis of a depressive dis-
order prior to CDI. The rates of CDI in the reference
population (fee-for-service Medicare population in the
USA) are given in Table 1, stratified by major depres-
sion. The rate of CDI was 282.9 per 100,000 person-
years in those with depression, and 197.1 per 100,000
person-years in those without depression.
After adjusting for demographic characteristics, comorbidities
and frequency of medical visits, there was a 36% in-
crease in the odds of developing CDI for individuals
with major depression compared with those without
major depression (Table 2). The findings were similar
for depressive disorders (OR = 1.35), feelings of sadness
(OR = 1.41) and emotional, nervous or psychiatric prob-
lems (OR = 1.47). Older Americans who were widowed
were significantly more likely to develop CDI; the odds
of CDI were 54% greater in older adults who were
widowed compared with those who were married. Being
divorced or separated was significantly associated with
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CDI in the unadjusted model but not in the fully ad-
justed model (P = 0.072). Developing CDI was also more
common in older adults who lived alone; individuals
who lived with others had a 25% decrease in the odds of
developing CDI compared with those who lived alone.
Study 2
In Study 2, there were 4,047 adult patients who had their
stools tested for C. difficile during hospitalization within
the UMHS from 1 August 2010 to 29 February 2012. Of
these subjects, 468 tested positive (cases) and 3579 tested
negative (controls). The characteristics of the patients
are given in Table 3 and show that the cases and controls
were similar with regard to age, gender, race, type of
admission, number of days from admission to the time of
stool collection for testing, and use of various medications
prior to stool collection. As seen in Table 3, 83.8% of
the cases and 82.6% of the controls had received antibi-
otics (P = 0.530). We also had data for both antibiotics
and anti-depressants. In this study, 82.8% of those receiv-
ing anti-depressants were given antibiotics, and 82.7% of
those not receiving anti-depressants were given antibiotics
(P = 0.957).
Certain anti-depressants were significantly related to
CDI (Table 4). The odds of testing positive for C. difficile
were twice as high in patients who received mirtazapine
than in those who did not (OR = 2.14). For each dose
of mirtazapine given, the odds of testing positive for C.
difficile increased by 8%. There was also an association
between fluoxetine and testing positive for C. difficile,
Table 1 Rate of Clostridium difficile infection by previous diagnosis of major depression in Medicare beneficiaries
Characteristics Sample,
n (%)
No depression Depression
Ratea 95% CI Ratea 95% CI
Age at first interviewb
<60 years 5277 (31.4) 125.1 82.2 to 168.0 332.9 193.5 to 472.2
60 to 75 years 7258 (43.3) 178.2 145.2 to 211.1 239.8 182.9 to 296.7
>75 years 4246 (25.3) 301.0 241.6 to 360.3 321.6 213.4 to 429.9
Gender
Men 7352 (43.8) 179.6 145.5 to 213.6 268.9 163.5 to 374.3
Women 9429 (56.2) 212.2 173.6 to 250.8 289.3 233.6 to 345.1
Race
African-American 2232 (13.3) 221.5 136.7 to 306.2 346.4 173.6 to 519.3
Other 14549 (86.7) 193.1 161.7 to 224.5 275.1 214.5 to 335.7
Ethnicity
Mexican-American 700 (4.2) 243.7 77.3 to 410.1 313.1 65.6 to 560.7
Other Hispanic 486 (2.9) 204.9 272.4 to 382.6 234.2 129.8 to 338.6
Non-Hispanic 15595 (92.9) 195.1 165.5 to 224.6 283.6 222.3 to 344.9
Body mass index
<18.5 kg/m2 366 (2.2) 348.2 87.9 to 608.6 475.5 115.3 to 835.6
18.5 to 24.9 kg/m2 6311 (37.6) 185.0 149.2 to 220.8 279.0 185.7 to 372.2
25.0 to 29.9 kg/m2 6851 (40.8) 188.4 151.7 to 225.1 300.8 210.7 to 390.9
≥30.0 kg/m2 3253 (19.4) 225.4 160.6 to 290.1 234.9 133.5 to 336.3
Education
No high-school degree 5691 (33.9) 247.6 203.2 to 291.9 254.4 170.5 to 338.2
High-school degree 11090 (66.1) 172.1 137.7 to 206.5 299.6 234.0 to 365.3
Region of residence
Northeast 2958 (17.6) 265.3 193.1 to 337.4 366.5 194.9 to 538.1
Midwest 4205 (25.1) 226.6 155.5 to 297.8 307.0 191.5 to 422.5
South 6823 (40.7) 176.5 135.4 to 217.7 257.5 185.6 to 329.5
West 2795 (16.7) 136.1 85.4 to 186.7 218.8 115.6 to 322.0
Overall 16781 197.1 168.0 to 226.1 282.9 226.3 to 339.5
aNumber of individuals with CDI/100,000 person-years.
bAge range 36 to 103 years.
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with an OR of 1.92 after adjustment. For each dose of
fluoxetine received, the odds of testing positive increased
by 6%. Other selective serotonin reuptake inhibitors
(SSRIs), besides fluoxetine, were not significantly associ-
ated with a positive CDI test. Of the tricyclic anti-
depressants, each dose of nortriptyline was associated
with an 11% increase in the odds of testing positive for
C. difficile, although the OR for use (yes/no) was not sig-
nificant at the 0.05 alpha level (P = 0.062). The
remaining anti-depressants were not associated with a
positive C. difficile test.
In a secondary analysis, we considered whether inter-
actions between anti-depressants could alter the risk of
developing CDI. There was a significant interaction be-
tween mirtazapine and trazodone (P = 0.040 for the
interaction term). For a patient receiving both of these
anti-depressants, the odds of a positive C. difficile test
were 5.72 times greater than in individuals receiving nei-
ther of these drugs (95% CI 2.01, 16.26; P = 0.001). Of
the patients receiving mirtazapine only, 21.2% had a
positive C. difficile test, whereas of the patients receiving
trazodone only, fewer (13.6%) had a positive test. Of the
patients receiving both mirtazapine and trazodone,
43.7% subsequently had a positive C. difficile test.
In a sensitivity analysis using a case-crossover design in
which patients (n = 406) served as their own controls, the
interaction between mirtazapine and trazodone remained
significant (P = 0.010) after adjustment for antibacterial
medications, statins, immunosuppressant medications, red
blood cell transfusions, PPIs, and H2RAs (Table 5). The
odds of CDI were greater during hospitalizations in which
the patients received mirtazapine with trazodone com-
pared with hospitalizations in which these same patients
did not receive these two anti-depressants. However,
the attributable risk associated with these two drugs
was small, because the percentage of hospitalizations in
which patients received both of these anti-depressants was
only 1.25%.
Table 2 Odds ratios for Clostridium difficile infection and previous depression-related conditions in Medicare
beneficiaries
Unadjusted Adjusted for age, gender, race Fully adjusteda
Conditions OR 95% CI P value OR 95% CI P value OR 95% CI P value
Depression
Yes 1.45 1.14 to 1.86 0.003 1.41 1.10 to 1.82 0.008 1.36 1.06 to 1.74 0.016
No 1.00 (reference) 1.00 (reference) 1.00 (reference)
Depressive disorders
Yes 1.44 1.13 to 1.85 0.004 1.40 1.08 to 1.80 0.011 1.35 1.05 to 1.73 0.021
No 1.00 (reference) 1.00 (reference) 1.00 (reference)
Feeling sad
Yes 1.62 1.27 to 2.06 <0.001 1.48 1.16 to 1.90 0.002 1.41 1.10 to 1.81 0.008
No 1.00 (reference) 1.00 (reference) 1.00 (reference)
Emotional, nervous or psychiatric problems
Yes 1.45 1.02 to 2.05 0.038 1.55 1.08 to 2.21 0.017 1.47 1.02 to 2.11 0.041
No 1.00 (reference) 1.00 (reference) 1.00 (reference)
Psychiatrist visit
Yes 1.42 1.10 to 1.83 0.008 1.35 1.05 to 1.72 0.020 1.26 0.95 to 1.67 0.104
No 1.00 (reference) 1.00 (reference) 1.00 (reference)
Marital status
Widowed 1.84 1.49 to 2.28 <0.001 1.59 1.26 to 2.02 <0.001 1.54 1.21 to 1.95 0.001
Divorced/separated 1.63 1.02 to 2.58 0.040 1.66 1.02 to 2.70 0.043 1.54 0.96 to 2.45 0.072
Single 1.29 0.63 to 2.65 0.473 1.27 0.61 to 2.63 0.518 1.28 0.62 to 2.66 0.499
Married 1.00 (reference) 1.00 (reference) 1.00 (reference)
Multiple people in household
Yes 0.67 0.55 to 0.81 <0.001 0.71 0.58 to 0.88 0.002 0.75 0.62 to 0.92 0.007
No 1.00 (reference) 1.00 (reference) 1.00 (reference)
aAdjusted for year of birth (centered), gender, race, ethnicity, BMI, smoking, end-stage renal disease, Crohn’s disease, celiac disease, ulcerative colitis, irritable
bowel disease, number of infection-related visits, total number of medical-related visits, and calendar year of first interview.
Rogers et al. BMC Medicine 2013, 11:121 Page 5 of 11
http://www.biomedcentral.com/1741-7015/11/121
Discussion
Our findings suggest that depression and/or the use of
specific anti-depressants are associated with develop-
ment of CDI. Data from this nationally representative
sample of older Americans show that population-based
rates (which include both community-acquired and
hospital-acquired disease) are greater in individuals with
major depression and depressive disorders, and in
people who reported feeling sad or having emotional,
nervous, or psychiatric problems, after adjustment for
confounders. In addition, widowed individuals and those
living alone were significantly more likely to develop
CDI. Results from our clinical study indicate that there
may be certain anti-depressants that impart an altered
risk for CDI, particularly the combination of mirtazapine
with trazodone. Such effects were independent of anti-
biotic use.
There is experimental and epidemiologic evidence to
support the hypothesis that depression and bereavement
result in changes in the gastrointestinal (GI) system
[7-10,15-17]. In a mouse model, depression (that is, ma-
ternal separation) was shown to result in both the devel-
opment and greater severity of colitis [10]. In humans,
pyrosequencing analysis of fecal microbiota of depressed
patients showed distinct bacterial phylotypes compared
with those found in patients without depression [16].
Moreover, patients with depressive symptoms exhibit
greater and more prolonged inflammatory responses
after antigen challenge than individuals without depres-
sive symptoms, suggesting that depression may result in
immune dysregulation [18]. Bereavement has also been
shown to decrease production of neutrophil superoxides
in older adults [19] and to reduce the functional activity
of natural killer cells [20]. It is possible that the physio-
logic sequelae of depression itself, and not anti-
depressants per se, may be associated with CDI risk.
It has been suggested that the mechanisms underlying
the brain–gut axis may be bidirectional [21-23]. In a 12-
year prospective study, the relationship between anxiety,
depression, and functional GI disorders appeared to be
bidirectional, in that psychiatric disorders predicted GI
disease and vice versa [21]. A population-based longitu-
dinal study in the Netherlands found similar results; the
risk of developing severe bowel disease was significantly
higher in individuals with previous depression, and the
risk of developing depression was significantly higher in
individuals who had previously experienced severe bowel
disease [22]. The authors concluded that depression and
severe non-cancerous bowel disease were ‘varying ex-
pressions of a partly shared aetiological process.’ [23]
Animal studies have suggested similar effects, with the
possibility that this interplay may begin in early life
[23,24]. Our studies suggest that depression, widowhood,
living alone, and the use of antidepressant medications
preceded the onset of CDI. We found, in our nationally
representative sample, that 35% of those who developed
CDI were diagnosed with major depression before the
infection. However, we did not have the complete med-
ical history of the subjects prior to study entry and
therefore, cannot be certain whether CDI pre-dated
Table 3 Characteristics of hospitalized adults who tested positive (cases) and negative (controls) for Clostridium difficile
Characteristics Cases, n = 468 Controls, n = 3579 P value
Age, mean ± SDa 57.6 ± 17.5 58.8 ± 16.5 0.158
Female, n (%) 223 (47.6) 1723 (48.1) 0.841
Caucasian, n (%) 387 (82.7) 2927 (81.8)
African-American, n (%) 51 (10.9) 386 (10.8)
Other race/unknown, n (%) 30 (6.4) 266 (7.4) 0.727
Elective admission, n (%) 138 (29.5) 930 (26.0)
Urgent admission, n (%) 104 (22.2) 846 (23.6)
Emergent admission, n (%) 226 (48.3) 1803 (50.4) 0.268
Days until stool collection, median (IQR)b 6 (4 to 10) 6 (4 to 10) 0.273
Antibiotics, n (%) 392 (83.8) 2956 (82.6) 0.530
Immunosuppressants, n (%) 71 (36.4) 554 (35.0) 0.692
Proton-pump inhibitors, n (%) 268 (57.3) 2040 (57.0) 0.913
Histamine-2 receptor antagonists, n (%) 138 (29.5) 1061 (29.6) 0.944
Statins, n (%) 130 (27.8) 927 (25.9) 0.385
Anxiolytics, n (%) 67 (34.4) 499 (31.5) 0.419
Antipsychotics, n (%) 24 (12.3) 202 (12.7) 0.860
aAge range 18 to 100 years.
bNumber of days from admission to stool collection for Clostridium difficile testing, median and interquartile range (IQR).
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Table 4 Odds ratios for antidepressant medications and Clostridium difficile infection in hospitalized adults
Unadjusted Adjusteda
Medications Using medication, n OR 95% CI P value OR 95% CI P value
Noradrenergic and specific serotonergic anti-depressants
Mirtazapine
Use (versus no use) 99 2.11 1.29 to 3.45 0.003 2.14 1.30 to 3.52 0.003
Doses given, n 1.08 1.01 to 1.16 0.018 1.08 1.01 to 1.16 0.020
Selective serotonin reuptake inhibitors
Fluoxetine
Use (versus no use) 99 1.98 1.20 to 3.26 0.008 1.92 1.16 to 3.17 0.012
Doses given, n 1.06 1.00 to 1.12 0.036 1.06 1.00 to 1.12 0.046
Escitalopram
Use (versus no use) 80 0.97 0.48 to 1.95 0.929 0.98 0.48 to 1.97 0.945
Doses given, n 1.04 0.98 to 1.10 0.191 1.04 0.98 to 1.09 0.234
Citalopram
Use (versus no use) 310 0.90 0.62 to 1.32 0.599 0.90 0.62 to 1.31 0.569
Doses given, n 0.99 0.94 to 1.04 0.620 0.98 0.94 to 1.04 0.566
Sertraline
Use (versus no use) 207 0.90 0.58 to 1.42 0.666 0.88 0.56 to 1.39 0.583
Doses given, n 0.98 0.93 to 1.04 0.486 0.98 0.92 to 1.04 0.461
Paroxetine
Use (versus no use) 78 0.87 0.42 to 1.82 0.716 0.86 0.41 to 1.80 0.692
Doses given, n 0.98 0.88 to 1.09 0.693 0.98 0.88 to 1.09 0.680
Tricyclic anti-depressants
Nortriptyline
Use (versus no use) 49 1.98 0.98 to 4.00 0.056 1.96 0.97 to 3.97 0.062
Doses given, n 1.11 1.02 to 1.20 0.015 1.11 1.02 to 1.20 0.017
Amitriptyline
Use (versus no use) 63 1.45 0.73 to 2.88 0.284 1.43 0.72 to 2.84 0.307
Doses given, n 1.04 0.96 to 1.14 0.337 1.04 0.96 to 1.14 0.343
Serotonin antagonist and reuptake inhibitors
Trazodone
Use (versus no use) 405 1.23 0.91 to 1.66 0.182 1.21 0.90 to 1.65 0.211
Doses given, n 1.04 0.98 to 1.10 0.184 1.04 0.98 to 1.10 0.197
Serotonin-norepinephrine reuptake inhibitors
Duloxetine
Use (versus no use) 82 1.19 0.63 to 2.26 0.597 1.15 0.60 to 2.19 0.681
Doses given, n 1.01 0.94 to 1.09 0.690 1.01 0.94 to 1.09 0.788
Venlafaxine
Use (versus no use) 58 0.72 0.29 to 1.81 0.482 0.71 0.28 to 1.78 0.464
Doses given, n 1.05 0.95 to 1.16 0.367 1.05 0.94 to 1.16 0.401
Norepinephrine-dopamine reuptake inhibitors
Bupropion
Use (versus no use) 97 1.08 0.59 to 2.00 0.801 1.02 0.55 to 1.89 0.948
Doses given, n 0.95 0.85 to 1.06 0.357 0.94 0.85 to 1.05 0.306
a. Adjusted for age, gender, race, antibacterial medications, PPIs, H2RAs, statins, irritable bowel syndrome, celiac disease, Crohn’s disease, and ulcerative colitis.
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study entry for some of the subjects. It is possible that
there is a lifelong liaison between the gut microbiota and
neurologic response to external stimuli.
In our population-based Study 1, individuals with
major depression had rates of C. difficile infection that
were consistently elevated across all age groups (Table 1).
For people without major depression, the rates of CDI
increased with age. Note that the rate of CDI was 332.9/
100,000 person-years in the youngest age group of pa-
tients with depression, whereas it was 301.0/100,000
person-years in the oldest age group for those without
depression. If CDI were a crude indicator of gut health,
it would seem that the microbiota of people with depres-
sion may be more similar to that of the very aged. Stud-
ies of the microbiota of older adults generally show less
diversity, particularly in those who live in long-term resi-
dential care compared with community dwellers [25].
The relationship between depression and inflammatory
bowel disease is well known [11,12,26]. A strong associ-
ation between anti-depressants and inflammatory pouch
syndrome has also been shown (adjusted OR of 4.17;
P = 0.0002) [27]. Because of this, we adjusted for Crohn’s
disease and ulcerative colitis in our studies, but the rela-
tionship between depression and CDI remained. This
may indicate that mechanisms underlying colitis due to
CDI and colitis due to inflammatory bowel disease share
commonality, both involving host immune response and
gut microbiota. When considered independently, each of
these types of colitis was associated with depression.
We cannot completely discern whether it is the patho-
physiology of depression itself or the treatment for de-
pression that is the major driver of these findings. In the
case–control study, we categorized the anti-depressants
by their mechanism of action, but this categorization did
not perfectly discriminate between the drugs that were
associated with higher CDI risk from those that were
not. It is widely appreciated that the mechanisms of ac-
tion of many anti-depressants are complex, and all their
effects (both intended effects and side-effects) are not
fully characterized. Many of the anti-depressants work
by altering serotonin levels and, in an animal model,
Ghia and colleagues found that serotonin plays a key
role in the pathogenesis of colitis [28]. However, even
anti-depressants within the same general class may have
slightly different actions; for example, fluoxetine has a
longer half-life than other SSRIs, and has a greater inci-
dence of weight loss and stimulant effects [29]. It is also
possible that inter-patient variation in genes encoding
for serotonin receptors may play a role in mediating
responses to therapy. For example, in a double-blind
randomized controlled trial of older patients taking
mirtazapine versus those taking paroxetine, side-effects
were strongly associated with the HTR2A C/C genotype
in those receiving paroxetine but there was no effect
with mirtazapine, suggesting that underlying genetic
markers can also affect the mechanism of action [30]. In
our investigation, the case-crossover design provided
some insights regarding discrimination between effects
due to the pathophysiology of depression itself versus
those due to specific anti-depressants. In this study, per-
sonal history of depression was, by design, held constant
because of the within-person comparison and therefore,
any difference found in antidepressant use was not due
to a history of depression. In effect, we measured drug
Table 5 Odds ratios for antidepressant medications and Clostridium difficile infection; case-crossover study of
hospitalized adults
Medication Hospitalizations, na ORb 95% CI P value
Fluoxetine 53 1.74 0.46 to 6.65 0.416
Escitalopram 25 0.57 0.12 to 2.79 0.491
Citalopram 128 0.41 0.17 to 0.99 0.047
Sertraline 105 0.58 0.21 to 1.57 0.282
Paroxetine 18 4.71 0.88 to 25.33 0.071
Nortriptyline 30 0.22 0.02 to 2.13 0.190
Amitriptyline 38 1.20 0.30 to 4.79 0.800
Duloxetine 37 0.44 0.10 to 1.89 0.267
Venlafaxine 27 5.05 0.58 to 44.15 0.143
Bupropion 36 0.48 0.11 to 2.05 0.323
Mirtazapine 64 0.82 0.31 to 2.13 0.682
Trazodone 171 0.55 0.33 to 0.90 0.018
Mirtazapine and trazodonec 17 32.54 2.29 to 462.9 0.010
aNumber of hospitalizations in which medication was administered.
bAdjusted for antibacterial medications, PPIs, H2RAs, statins, immunosuppressants and transfusion of red blood cells.
cReference category: no mirtazapine and no trazodone.
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use at different times (hospitalizations) in the same indi-
vidual. In these analyses, we found that usage of most
types of anti-depressants did not affect the likelihood of
developing CDI. However, in a small group of patients,
there was a significantly higher risk of CDI when taking
both mirtazapine and trazodone together. The use of
trazodone alone appeared protective, but when com-
bined with mirtazapine, the risk was increased. Larger
studies are necessary for confirmation of these findings.
However, this only occurred in a minority of patients
with CDI, which suggests that, for most patients, there
are underlying pathophysiologic mechanisms of depres-
sion that result in their increased risk of CDI, independ-
ent of antidepressant use.
Whereas antibiotic use was closely associated with
CDI, it was not evident that the link between depression
and CDI was due to increased physician prescriptions
for antibiotics in individuals with depression. In Study 2,
we had a tightly matched group of controls to cases with
respect to antibiotic use. All subjects were individuals
whose stool samples were tested for C. difficile, and
these tests were ordered when antibiotic-associated diar-
rhea was evident. We found that 83.8% of the cases and
82.6% of the controls had received antibiotics (P =
0.530). Furthermore, 82.8% of those receiving anti-
depressants and 82.7% of those not receiving anti-
depressants had been given antibiotics (P = 0.957). Ad-
justment for antibiotic use in the regression models (and
for the number of doses of antibiotics) did not change
the results.
Our investigation was limited by its observational de-
sign, especially for the assessment of anti-depressants,
because effects of medication are best addressed through
trials. However, CDI is not a common outcome, and a
trial of such unintended effects may not be feasible. Al-
though the relationship between anti-depressants and
CDI was first reported in a study conducted in two hos-
pitals [5], the types of anti-depressants in that study
were not listed and therefore, we cannot adequately as-
sess the similarity of results across hospitals. In Study 1,
the use of a nationally representative sample that cap-
tured both outpatient visits and inpatient stays over an
extended period (17 years maximum) was a strength for
the assessment of depression, widowhood, and other fac-
tors in which randomization is not possible.
A limitation of Study 1 was the use of physician diag-
noses to detect depression, which may underestimate
the true frequency of this disease. However, data from
the HRS contain additional information beyond phys-
ician diagnoses. Information was available from self-
report by participants during biennial interviews. The
variables shown in Table 2 relate to depression measured
in different ways and the ORs all tended to show a simi-
lar pattern. For example, patient self-report of feeling
sad (irrespective of a physician’s diagnosis) was signifi-
cantly associated with CDI. The OR was 1.41 (P = 0.008)
which parallels the findings for a physician diagnosis of
major depression (OR = 1.36, P = 0.016). Moreover, if
underestimation of depression is present through missed
diagnoses, it is likely to be non-differential misclassifica-
tion; that is, the under-reporting of depression could
occur in both people who have and people who do not
have CDI. There is currently no established link between
depression and CDI in the medical literature by which
physicians across the country would link these two con-
ditions. When such non-differential misclassification oc-
curs, the OR tends to be pulled towards the null. Thus,
if under-diagnosis of depression does occur, we would
expect that the true (reference population) OR would be
greater than 1.36.
Another concern may be testing bias, which would
occur if the ordering of a test for C. difficile occurs at
different rates in persons with and without depression.
In Study 2, participants were all patients who were
tested for C. difficile during a given time period because
of symptoms evidenced during hospitalization; that is,
antibiotic-associated diarrhea. Because depression has
not been previously correlated with CDI in the medical
literature or in general clinical practice, we do not sus-
pect that there was differential testing based on this spe-
cific diagnosis.
Unfortunately, questions regarding dietary intake were
not asked of all participants in the HRS as a part of the
ongoing biennial interview, nor did we have dietary
intake information on the hospitalized patients in Study
2. Therefore, the influence of habitual diet on both de-
pression and CDI cannot be assessed in our studies.
There was one aspect of our investigation, however,
in which we were able to control for past dietary intake.
In the sensitivity study of the hospitalized patients
(Study 2), we conducted a case-crossover study whereby
each person was compared with him/herself. In this in-
stance, past dietary habits (prior to July 2009) were held
constant; such habits are the same because the person is
the same. When diet was held constant, patients receiv-
ing mirtazapine with trazodone were at greater risk of
developing CDI. However, if some of these patients
began eating differently after July 2009, such differences
could not be measured. Overall, the effect of diet on
both depression and CDI would be an interesting area
for further study.
Conclusions
Given the rise of CDI, especially among older individuals
[31], elucidating the modifiable risk factors for this
often-fatal illness is an important patient safety issue.
Our complementary studies reveal that adults with de-
pression and those that use specific anti-depressants
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seem to be more likely to experience CDI. Widowhood
and living alone are also associated with CDI. Clinicians
prescribing antimicrobials to patients with depression
should be aware of the possible increased risk of CDI in
this patient population.
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